Concomitant use of statins and s-(2-boron-ethyl)-l-cysteine arginase inhibitor to correct endotoxin-induced endothelial dysfunction

The concomitant use of non-selective S-(2-boron-ethyl)-L-cysteine (BEC) arginase inhibitor with simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of endotoxin-induced disorder modeling by Staphylococcus aureus (strain 13407) injection under the skin – 60 billions of microbial bodies – exhibits an endothelium- and cardioprotective action which is evident as endothelial dysfunction factor (EDF) increase prevention, adrenoreactivity, maintenance of myocardial reserve, and normalization of biochemical markers (total NO, expression of eNOS, C-reactive protein, IL-6, tumor necrosis factor

Combination of captopril and darbepoetin alfa attenuate radiation-induced-endothelial dysfunction

The combination of captopril + darbepoetin alfa has a high radio- and endothelioprotective potential and can be recommended for further preclinical and clinical studie

Lawson criterion for ignition exceeded in an inertial fusion experiment

For more than half a century, researchers around the world have been engaged in attempts to achieve fusion ignition as a proof of principle of various fusion concepts. Following the Lawson criterion, an ignited plasma is one where the fusion heating power is high enough to overcome all the physical processes that cool the fusion plasma, creating a positive thermodynamic feedback loop with rapidly increasing temperature. In inertially confined fusion, ignition is a state where the fusion plasma can begin "burn propagation" into surrounding cold fuel, enabling the possibility of high energy gain. While "scientific breakeven" (i.e., unity target gain) has not yet been achieved (here target gain is 0.72, 1.37 MJ of fusion for 1.92 MJ of laser energy), this Letter reports the first controlled fusion experiment, using laser indirect drive, on the National Ignition Facility to produce capsule gain (here 5.8) and reach ignition by nine different formulations of the Lawson criterion

Concomitant use of statins and s-(2-boron-ethyl)-l-cysteine arginase inhibitor to correct endotoxin-induced endothelial dysfunction

The concomitant use of non-selective S-(2-boron-ethyl)-L-cysteine (BEC) arginase inhibitor with simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of endotoxin-induced disorder modeling by Staphylococcus aureus (strain 13407) injection under the skin – 60 billions of microbial bodies – exhibits an endothelium- and cardioprotective action which is evident as endothelial dysfunction factor (EDF) increase prevention, adrenoreactivity, maintenance of myocardial reserve, and normalization of biochemical markers (total NO, expression of eNOS, C-reactive protein, IL-6, tumor necrosis factor

ENDOTHELIAL DYSFUNCTION UNDER INFLUENCE OF IONIZING RADIATION: PATHOGENETIC BASIS AND OPPORTUNITIES OF PHARMACOLOGICAL CORRECTION

The problem of radiation-induced lesions is becoming increasingly urgent. Studies in recent years show that one of the most vulnerable  tissues is the endothelium when exposed to high doses of ionizing  radiation. The study of the pathogenetic bases of this phenomenon has  shown that damage to endotheliocytes occurs both at the expense of  the direct exposure to radiation and due to the systemic disturbance of  homeostasis which leads to the disadaptation of the executive and  regulatory systems of the organism. In this review we considered the  mechanisms of the development of endothelial dysfunction under the influence of radioactive radiation and possible methods of pharmacological correction of this condition